The KRAS G12C Inhibitor Divarasib Stabilizes RBM39 and Antagonizes Aryl-Sulfonamide Degraders
Ssu-Yu Chen, You Zou, Jianli Wu, Gibeom Nam, Hyejin Lee, Yubin Chen, Chiara Federico, Yasaman Setayeshpour, Chao‐Chieh Lin, Shao-Chin Wu, J.H. Strickler, Jiyong Hong, Michael C. Fitzgerald, Jen‐Tsan Chi
This study identifies RBM39 as a noncovalent target of the KRAS G12C inhibitor divarasib and reveals an RBM39-INSR signaling axis that influences cytotoxicity.
bioRxiv · Aug 20, 2026 · PreprintPharmacology & Toxicology